OM:SPRINT

Stock Analysis Report

Executive Summary

Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism.

Snowflake

Fundamentals

Mediocre balance sheet and overvalued.

Risks

  • Sprint Bioscience has significant price volatility in the past 3 months.
  • Sprint Bioscience is not covered by any analysts.

Share Price & News

How has Sprint Bioscience's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

13.4%

OM:SPRINT

2.5%

SE Biotechs

2.2%

SE Market


1 Year Return

10.8%

OM:SPRINT

-18.5%

SE Biotechs

-2.1%

SE Market

SPRINT outperformed the Biotechs industry which returned -18.9% over the past year.

SPRINT outperformed the Market in Sweden which returned -2.3% over the past year.


Share holder returns

SPRINTIndustryMarket
7 Day13.4%2.5%2.2%
30 Day5.3%-7.9%-3.4%
90 Day22.8%-2.0%0.5%
1 Year10.8%10.8%-18.1%-18.5%2.0%-2.1%
3 Year-55.4%-55.4%42.2%31.2%24.9%6.4%
5 Yearn/a54.2%53.6%45.2%14.5%

Price Volatility Vs. Market

How volatile is Sprint Bioscience's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Sprint Bioscience undervalued based on future cash flows and its price relative to the stock market?

3.62x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Sprint Bioscience to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Sprint Bioscience to establish if it is available at substantial discount.


Price Based on Earnings

Sprint Bioscience is loss making, we can't compare its value to the SE Biotechs industry average.

Sprint Bioscience is loss making, we can't compare the value of its earnings to the Sweden market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Sprint Bioscience, we can't assess if its growth is good value.


Price Based on Value of Assets

Sprint Bioscience is good value based on assets compared to the SE Biotechs industry average.


Next Steps

Future Growth

How is Sprint Bioscience expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

12.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sprint Bioscience has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Sprint Bioscience performed over the past 5 years?

-13.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Sprint Bioscience does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Sprint Bioscience's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Sprint Bioscience's 1-year growth to the SE Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Sprint Bioscience has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Sprint Bioscience has efficiently used its assets last year compared to the SE Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Sprint Bioscience improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Sprint Bioscience's financial position?


Financial Position Analysis

Sprint Bioscience is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Sprint Bioscience's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Sprint Bioscience has no debt.

Sprint Bioscience has no debt compared to 5 years ago when it was 73.5%.


Balance Sheet

Low level of unsold assets.

Sprint Bioscience has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Sprint Bioscience has less than a year of cash runway based on current free cash flow.

Sprint Bioscience has less than a year of cash runway if free cash flow continues to grow at historical rates of 72.3% each year.


Next Steps

Dividend

What is Sprint Bioscience's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Sprint Bioscience's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Sprint Bioscience's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Sprint Bioscience has not reported any payouts.

Unable to verify if Sprint Bioscience's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Sprint Bioscience has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Sprint Bioscience's salary, the management and board of directors tenure and is there insider trading?

5.6yrs

Average management tenure


CEO

Jessica Martinsson (47yo)

0.2yrs

Tenure

0

Ms. Jessica Martinsson, MSc Co-founded Sprint Bioscience AB in February 2009 and serves as its Acting Chief Executive Officer since June 11, 2019 and serves as its Head of Operations until June 11, 2019. M ...


Management Age and Tenure

5.6yrs

Average Tenure

52.5yo

Average Age

The average tenure for the Sprint Bioscience management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

1.3yrs

Average Tenure

63yo

Average Age

The average tenure for the Sprint Bioscience board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Anders Åberg (61yo)

    Founder & Senior Adviser

    • Tenure: 10.6yrs
    • Compensation: kr1.32m
  • Pär Nordlund (61yo)

    • Tenure: 0.0yrs
    • Compensation: kr25.00k
  • Martin Andersson (48yo)

    Founder & Head of Research

    • Tenure: 10.6yrs
  • Jessica Martinsson (47yo)

    Founder & Acting CEO

    • Tenure: 0.2yrs
  • Kenth Hallberg (48yo)

    Founder & Director of Structural Chemistry

    • Tenure: 0.0yrs
  • Anne-Marie Wenthzel

    Head of Business Development

    • Tenure: 0.0yrs
  • Karin Liwendahl (57yo)

    Chief Financial Officer

    • Tenure: 0.6yrs

Board Members

  • Rune Nordlander (63yo)

    Chairman

    • Tenure: 9.6yrs
    • Compensation: kr167.00k
  • Charlotta Liljebris

    Director

    • Tenure: 2.3yrs
    • Compensation: kr58.00k
  • Fredrik Lehman (43yo)

    Director

    • Tenure: 0.3yrs
  • Jan-Erik Nyström (66yo)

    Director

    • Tenure: 0.3yrs

Company Information

Sprint Bioscience AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sprint Bioscience AB (publ)
  • Ticker: SPRINT
  • Exchange: OM
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr197.087m
  • Shares outstanding: 11.63m
  • Website: https://www.sprintbioscience.com

Location

  • Sprint Bioscience AB (publ)
  • Novum
  • Hälsovägen 7, 8th floor
  • Huddinge
  • Stockholm County
  • 141 57
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SPRINTOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKNov 2014

Biography

Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism. It engages in developing STK25, a drug candidate against a new target protein for the treatment of type 2 ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/21 21:45
End of Day Share Price2019/08/21 00:00
Earnings2019/03/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.